Cargando…

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease

BACKGROUND: Intravenous iron is often used to treat iron deficiency anaemia in non-dialysis chronic kidney disease (ND-CKD), but the optimal dosing regimen remains unclear. We evaluated the impact of high- versus low-dose intravenous iron isomaltoside on the probability of retreatment with intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalra, Philip A., Bhandari, Sunil, Spyridon, Michael, Davison, Rachel, Lawman, Sarah, Mikhail, Ashraf, Reaich, David, Pritchard, Nick, McCafferty, Kieran, Moore, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726614/ https://www.ncbi.nlm.nih.gov/pubmed/33302891 http://dx.doi.org/10.1186/s12882-020-02180-2

Ejemplares similares

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
por: Frigstad, Svein Oskar, et al.
Publicado: (2017)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
por: Jensen, Gert, et al.
Publicado: (2019)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
por: Jesus-Silva, Jorge A., et al.
Publicado: (2020)

A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000
por: Bhandari, Sunil
Publicado: (2011)

Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
por: Kalra, Philip A.
Publicado: (2011)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
por: Pollock, Richard F, et al.
Publicado: (2017)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO)
por: Mikhail, Ashraf I., et al.
Publicado: (2019)

A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD
por: Greenwood, Sharlene A., et al.
Publicado: (2023)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial
por: Fung, Pui Lam Polly, et al.
Publicado: (2022)

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
por: Dahlerup, Jens Frederik, et al.
Publicado: (2016)

A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia
por: Mercadal, Lucile, et al.
Publicado: (2014)

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
por: Riccio, Eleonora, et al.
Publicado: (2020)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial
por: Markova, Veronika, et al.
Publicado: (2020)

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

Correction: A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia
Publicado: (2014)

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
por: Birgegård, Gunnar, et al.
Publicado: (2016)

Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis
por: Goh, Hyeok Jun, et al.
Publicado: (2020)

Role of NiMo Alloy and Ni Species in the Performance of NiMo/Alumina Catalysts for Hydrodeoxygenation of Stearic Acid: A Kinetic Study
por: Kumar, Pankaj, et al.
Publicado: (2019)

Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK
por: Aksan, Aysegül, et al.
Publicado: (2021)

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Iron Absorption Tests in Anæmia: The Use of Intravenous Iron Preparations
por: Crawley, Joan
Publicado: (1952)

Hypochromic Anaemias Not Due to Iron Deficiency: Thalassaemia and Sideroblastic Anaemia
por: Weatherall, D. J.
Publicado: (1969)

Iron Incorporation and Post-Malaria Anaemia
por: Doherty, Conor P., et al.
Publicado: (2008)

Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
por: Berber, Ilhami, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cltdodc5d74bv03ctvl7vjl7ar